143 related articles for article (PubMed ID: 32911601)
41. Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study.
Cauldwell M; Mackie FL; Steer PJ; Henehghan MA; Baalman JH; Brennand J; Johnston T; Dockree S; Hedley C; Jarvis S; Khan S; McAuliffe FM; Mackillop L; Penna L; Smith B; Trivedi P; Verma S; Westbrook R; Winifield S; Williamson C
BJOG; 2020 Jun; 127(7):876-884. PubMed ID: 32012415
[TBL] [Abstract][Full Text] [Related]
42. Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis.
Haruta I; Hashimoto E; Kato Y; Kikuchi K; Kato H; Yagi J; Uchiyama T; Kobayash M; Shiratori K
Autoimmunity; 2006 Mar; 39(2):129-35. PubMed ID: 16698669
[TBL] [Abstract][Full Text] [Related]
43. [Importance of liver puncture biopsy and endoscopic retrograde cholangiography in patients with chronic anicteric unexplained cholestasis. A retrospective study in 79 patients].
Sapey T; Turlin B; Canva-Delcambre V; Mendler MH; Deugnier Y; Brissot P; Guyader D
Gastroenterol Clin Biol; 1999 Feb; 23(2):178-85. PubMed ID: 10353011
[TBL] [Abstract][Full Text] [Related]
44. Chronic cholestatic diseases.
Poupon R; Chazouillères O; Poupon RE
J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
[TBL] [Abstract][Full Text] [Related]
45. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis.
Sakisaka S; Kawaguchi T; Taniguchi E; Hanada S; Sasatomi K; Koga H; Harada M; Kimura R; Sata M; Sawada N; Mori M; Todo S; Kurohiji T
Hepatology; 2001 Jun; 33(6):1460-8. PubMed ID: 11391535
[TBL] [Abstract][Full Text] [Related]
46. Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration.
Arrese M; Pizarro M; Solís N; Koenig C; Accatino L
Biochem Pharmacol; 1995 Oct; 50(8):1223-32. PubMed ID: 7488238
[TBL] [Abstract][Full Text] [Related]
47. [Clinicopathological analysis of anti-mitochondrial antibody negative primary biliary cholangitis-autoimmune hepatitis overlap syndrome].
Tan XY; Miao Q; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):376-380. PubMed ID: 31177663
[No Abstract] [Full Text] [Related]
48. Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis.
Guañabens N; Ruiz-Gaspà S; Gifre L; Miquel R; Peris P; Monegal A; Dubrueil M; Arias A; Parés A
J Bone Miner Res; 2016 Sep; 31(9):1725-33. PubMed ID: 27019303
[TBL] [Abstract][Full Text] [Related]
49. [Autoimmune liver diseases and their overlap syndromes].
Strassburg CP
Praxis (Bern 1994); 2006 Sep; 95(36):1363-81. PubMed ID: 16989180
[TBL] [Abstract][Full Text] [Related]
50. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.
Degiorgio D; Crosignani A; Colombo C; Bordo D; Zuin M; Vassallo E; Syrén ML; Coviello DA; Battezzati PM
J Gastroenterol; 2016 Mar; 51(3):271-80. PubMed ID: 26324191
[TBL] [Abstract][Full Text] [Related]
51. [Clinicopathological features of early- and late-stage primary biliary cirrhosis: a comparative study].
Zhao SX; Zhang YG; Zhou GD; Wang RQ; Zhang QS; Li WC; Ren WG; Nan YM; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):412-6. PubMed ID: 27465943
[TBL] [Abstract][Full Text] [Related]
52. Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms.
Bombaci M; Pesce E; Torri A; Carpi D; Crosti M; Lanzafame M; Cordiglieri C; Sinisi A; Moro M; Bernuzzi F; Gerussi A; Geginat J; Muratori L; Terracciano LM; Invernizzi P; Abrignani S; Grifantini R
Liver Int; 2019 Nov; 39(11):2124-2135. PubMed ID: 31033124
[TBL] [Abstract][Full Text] [Related]
53. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
54. Cholestatic liver diseases: new targets, new therapies.
Santiago P; Scheinberg AR; Levy C
Therap Adv Gastroenterol; 2018; 11():1756284818787400. PubMed ID: 30159035
[TBL] [Abstract][Full Text] [Related]
55. Altered expression of alkaline phosphatase (ALP) in the liver of primary biliary cirrhosis (PBC) patients.
Suzuki N; Irie M; Iwata K; Nakane H; Yoshikane M; Koyama Y; Uehara Y; Takeyama Y; Kitamura Y; Sohda T; Watanabe H; Ikehara Y; Sakisaka S
Hepatol Res; 2006 May; 35(1):37-44. PubMed ID: 16567122
[TBL] [Abstract][Full Text] [Related]
56. [Clinical and pathological characteristics of primary biliary cirrhosis].
Wang J; Jiang W; Gao H; He B; Liu W
Zhonghua Gan Zang Bing Za Zhi; 2002 Oct; 10(5):334-7. PubMed ID: 12392609
[TBL] [Abstract][Full Text] [Related]
57. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
58. Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis.
Bauer A; Habior A
Ann Lab Med; 2019 May; 39(3):291-298. PubMed ID: 30623621
[TBL] [Abstract][Full Text] [Related]
59. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
60. Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease.
Azer SA; Coverdale SA; Byth K; Farrell GC; Stacey NH
J Gastroenterol Hepatol; 1996 Mar; 11(3):208-15. PubMed ID: 8742915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
